Monitoring of Chronic Conditions in Breast Cancer

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age19-80
SponsorHelse Stavanger HF

About this trial

REBECCA-1 is an observational study. Clinical research is undergoing a revolutionary change. The use of electronic patient records (EHR), digital registers, smartphones etc will create "real-world data" (RWD) that provides great opportunities for advancing clinical research, but so far this opportunity has been little exploited. The REBECCA -1 study will observe and monitor fatigue in breast cancer survivors. Investigators will use self reported questionnaires (PROM-data), blood tests and objective regulations like the REBECCCA -1 smart watch that will register amount of steps every day, leaving the house, visiting friends, cafes etc. There will be three observational arms; 1.high fatigue, 2. low fatigue and 3. a healthy control arm. After the patients have finished their treatment, they will receive the REBECCA smart watch, a REBECCA app on the smart phone and a REBECCA plus device on their computer, The next offend are also invited to report their evaluation through the same apps. The observational time will be 1 year and comparison between the subjective PROM data , the objective REBECCA watch and the biological samples will be obtained.

Eligibility criteria

Qualifiers

Breast cancer patients with histologically detectable M0 breast cancer (stage 0-III) who require neoadjuvant or adjuvant endocrine, chemo and / or radiation therapy at least and no more than 3 months before initiation of study.

Female breast cancer patients between 19 and 80 years of age.

Patients who have increased their life expectancy beyond the first 3 months after starting treatment.

Patients who have the ability to understand the protocol and can participate in the follow-up plan.

Disqualifiers

Male breast cancer patients.

Patients who do not agree to the study protocol.

Patients with a previous cancer diagnosis (excluding skin cancer treated only by surgery).

Patients who have previously been treated with some form of chemotherapy / radiation therapy.

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

150 Participants
are grouped into 3 trial groups

Sponsors and collaborators